Eye (London, England) · 2026
Two-year treatment outcomes in neovascular age-related macular degeneration with type 3 macular neovascularisation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fukuda Yosuke, Shiose Satomi, Notomi Shoji, Maehara Yusuke, Yuge Kodai, Kiyohara Kohei, Yasaka Yuta, Mori Kenichiro, Fujiwara Kohta, Kano Kumiko, Ishikawa Keijiro, Murakami Yusuke, Sonoda Koh-Hei
Аннотация
BACKGROUND: Neovascular age-related macular degeneration (nAMD) with type 3 macular neovascularisation (MNV) carries a high risk of macular atrophy (MA) during anti-vascular endothelial growth factor (anti-VEGF) treatment. Previous studies have suggested that a greater injection burden is associated with a higher MA risk. We evaluated 2-year outcomes of patients with nAMD with type 3 MNV following the treat and extend (TAE) and pro re nata (PRN) regimens and identified the risk factors for MA.
SUBJECTS: This retrospective study included 97 eyes of 68 treatment-naïve nAMD patients with type 3 MNV. All eyes received monthly anti-VEGF injections for 3 months as a loading phase and were followed for >2 years. Analyses were performed at the eye level for clinical outcomes; for risk-factor analyses of incident MA, one eye per patient was included. Outcomes included best-corrected visual acuity (BCVA) and central macular thickness (CMT).
RESULTS: Compared with PRN, TAE achieved better BCVA at 24 months (mean difference, -0.26 logMAR; 95% CI, -0.50 to -0.02). CMT was lower with TAE at 12 months (mean difference, -47.0 µm; 95% CI, -86.1 to -8.0). Retinal haemorrhage recurrence was less frequent with TAE (16.4% vs. 52.4%; risk difference, -36.0%; 95% CI, -57.8% to -9.5%). In multivariable models, greater injection number and thinner baseline central choroidal thickness were associated with incident MA (P < 0.05), whereas regimen type itself was not.
CONCLUSIONS: Despite a higher injection burden, TAE maintained superior functional outcomes over two years relative to PRN.
SUBJECTS: This retrospective study included 97 eyes of 68 treatment-naïve nAMD patients with type 3 MNV. All eyes received monthly anti-VEGF injections for 3 months as a loading phase and were followed for >2 years. Analyses were performed at the eye level for clinical outcomes; for risk-factor analyses of incident MA, one eye per patient was included. Outcomes included best-corrected visual acuity (BCVA) and central macular thickness (CMT).
RESULTS: Compared with PRN, TAE achieved better BCVA at 24 months (mean difference, -0.26 logMAR; 95% CI, -0.50 to -0.02). CMT was lower with TAE at 12 months (mean difference, -47.0 µm; 95% CI, -86.1 to -8.0). Retinal haemorrhage recurrence was less frequent with TAE (16.4% vs. 52.4%; risk difference, -36.0%; 95% CI, -57.8% to -9.5%). In multivariable models, greater injection number and thinner baseline central choroidal thickness were associated with incident MA (P < 0.05), whereas regimen type itself was not.
CONCLUSIONS: Despite a higher injection burden, TAE maintained superior functional outcomes over two years relative to PRN.
Предметные рубрики MeSH
HumansRetrospective StudiesFemaleVisual AcuityAngiogenesis InhibitorsMaleIntravitreal InjectionsVascular Endothelial Growth Factor ATreatment OutcomeAgedAged, 80 and overTomography, Optical CoherenceRanibizumabBevacizumabWet Macular DegenerationFluorescein AngiographyRisk FactorsFollow-Up StudiesMacula Lutea